 The regimen will be considered promising if the rate of responsefavorable outcome is 40 or greater. A rate of 20 similar to that observed for bicalutamide alone will not be considered worthy of further study. 38 patients of whom 36 are assumed to be eligible will be accrued to the study. If 11 or more patients have a favorable outcome stable disease 6 months or response, the combination will be considered worthy of further study. Given this design, there is a 9 probability of declaring the combination effective if the true favorable outcome rate is 20 and a 91 probability of declaring the combination effective if the true favorable outcome rate is 40. 